|
1
|
Makker V, MacKay H, Ray-Coquard I, Levine
DA, Westin SN, Aoki D and Oaknin A: Endometrial cancer. Nat Rev Dis
Primers. 7:882021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–49. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu KH and Broaddus RR: Endometrial cancer.
N Engl J Med. 383:2053–2064. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morice P, Leary A, Creutzberg C,
Abu-Rustum N and Darai E: Endometrial cancer. Lancet.
387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhaskaran K, Douglas I, Forbes H,
dos-Santos-Silva I, Leon DA and Smeeth L: Body-mass index and risk
of 22 specific cancers: A population-based cohort study of 5·24
million UK adults. Lancet. 384:755–765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Urick ME and Bell DW: Clinical
actionability of molecular targets in endometrial cancer. Nat Rev
Cancer. 19:510–521. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng Y, Li X, Dai Y, Dong Y, Yang X and
Wang J: Identification of an immune-related risk signature and
nomogram predicting the overall survival in patients with
endometrial cancer. J Gynecol Oncol. 32:e302021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu J, Ji C, Wang Y, Zhang C and Zhu H:
Identification of methylation-driven genes prognosis signature and
immune microenvironment in uterus corpus endometrial cancer. Cancer
Cell Int. 21:3652021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang H, Ma X, Liu J, Wan Y, Jiang Y, Xia Y
and Cheng W: Prognostic value of an autophagy-related gene
expression signature for endometrial cancer patients. Cancer Cell
Int. 20:3062020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang X, Li X, Cheng Y, Zhou J, Shen B,
Zhao L and Wang J: Comprehensive analysis of the glycolysis-related
gene prognostic signature and immune infiltration in endometrial
cancer. Front Cell Dev Biol. 9:7978262021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cancer Genome Atlas Research Network, .
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Prendergast EN, Holman LL, Liu AY, Lai TS,
Campos MP, Fahey JN, Wang X, Abdelaal N, Rao JY, Elvin JA, et al:
Comprehensive genomic profiling of recurrent endometrial cancer:
Implications for selection of systemic therapy. Gynecol Oncol.
154:461–466. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soumerai TE, Donoghue MTA, Bandlamudi C,
Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN,
O'Cearbhaill RE, Tew WP, et al: Clinical utility of prospective
molecular characterization in advanced endometrial cancer. Clin
Cancer Res. 24:5939–5947. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O'Malley D, Bariani GM, Cassier PA,
Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH Jr, Safra T,
Italiano A, Mileshkin L, et al: Pembrolizumab in patients with
microsatellite instability-high advanced endometrial cancer:
Results from the KEYNOTE-158 study. J Clin Oncol. 40:752–761. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
du Rusquec P, de Calbiac O, Robert M,
Campone M and Frenel JS: Clinical utility of pembrolizumab in the
management of advanced solid tumors: An evidence-based review on
the emerging new data. Cancer Manag Res. 11:4297–4312. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mutlu L, Harold J, Tymon-Rosario J and
Santin AD: Immune checkpoint inhibitors for recurrent endometrial
cancer. Expert Rev Anticancer Ther. 22:249–258. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bellone S, Roque DM, Siegel ER, Buza N,
Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi
S, et al: A phase II evaluation of pembrolizumab in recurrent
microsatellite instability-high (MSI-H) endometrial cancer patients
with Lynch-like versus MLH-1 methylated characteristics
(NCT02899793). Ann Oncol. 32:1045–1046. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hoy AJ, Nagarajan SR and Butler LM: Tumour
fatty acid metabolism in the context of therapy resistance and
obesity. Nat Rev Cancer. 21:753–766. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ji Z, Shen Y, Feng X, Kong Y, Shao Y, Meng
J, Zhang X and Yang G: Deregulation of lipid metabolism: The
critical factors in ovarian cancer. Front Oncol. 10:5930172020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoon H and Lee S: Fatty acid metabolism in
ovarian cancer: Therapeutic implications. Int J Mol Sci.
23:21702022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Darwish NM, Elshaer MMA, Almutairi SM,
Chen TW, Mohamed MO, Ghaly WBA and Rasheed RA: Omega-3
polyunsaturated fatty acids provoke apoptosis in hepatocellular
carcinoma through knocking down the STAT3 activated signaling
pathway: In vivo and in vitro study. Molecules. 27:30322022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang M, Dong X, Xiao L, Tan Z, Luo X, Yang
L, Li W, Shi F, Li Y, Zhao L, et al: CPT1A-mediated fatty acid
oxidation promotes cell proliferation via nucleoside metabolism in
nasopharyngeal carcinoma. Cell Death Dis. 13:3312022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen J, Chen J, Huang J, Li Z, Gong Y, Zou
B, Liu X, Ding L, Li P, Zhu Z, et al: HIF-2α upregulation mediated
by hypoxia promotes NAFLD-HCC progression by activating lipid
synthesis via the PI3K-AKT-mTOR pathway. Aging (Albany NY).
11:10839–10860. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ringel AE, Drijvers JM, Baker GJ, Catozzi
A, García-Cañaveras JC, Gassaway BM, Miller BC, Juneja VR, Nguyen
TH, Joshi S, et al: Obesity shapes metabolism in the tumor
microenvironment to suppress anti-tumor immunity. Cell.
183:1848–1866.e26. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Corn KC, Windham MA and Rafat M: Lipids in
the tumor microenvironment: From cancer progression to treatment.
Prog Lipid Res. 80:1010552020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rysman E, Brusselmans K, Scheys K,
Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D,
Daniëls VW, Machiels J, et al: De novo lipogenesis protects cancer
cells from free radicals and chemotherapeutics by promoting
membrane lipid saturation. Cancer Res. 70:8117–8126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hajjaji N and Bougnoux P: Selective
sensitization of tumors to chemotherapy by marine-derived lipids: A
review. Cancer Treat Rev. 39:473–488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang C, Huang X, Liu Z, Qin W and Wang C:
Metabolism-associated molecular classification of hepatocellular
carcinoma. Mol Oncol. 14:896–913. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding C, Shan Z, Li M, Chen H, Li X and Jin
Z: Characterization of the fatty acid metabolism in colorectal
cancer to guide clinical therapy. Mol Ther Oncolytics. 20:532–544.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Becht E, Giraldo NA, Lacroix L, Buttard B,
Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman
C, Fridman WH and de Reyniès A: Estimating the population abundance
of tissue-infiltrating immune and stromal cell populations using
gene expression. Genome Biol. 17:2182016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q,
Li B and Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune
cells. Nucleic Acids Res. 48:W509–W514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen Y, Liao Y, Du Q, Shang C, Qin S, Lee
K, Zou Q, Liu J and Yao S: Roles of pyroptosis-related gene
signature in prediction of endometrial cancer outcomes. Front Med
(Lausanne). 9:8228062022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu J, Wang Y, Meng H, Yin Y, Zhu H and Ni
T: Identification of the prognostic signature associated with tumor
immune microenvironment of uterine corpus endometrial carcinoma
based on ferroptosis-related genes. Front Cell Dev Biol.
9:7350132021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yin W, Liao F, Chen M, Qin X, Lai H, Lin Y
and Yao D: Immune infiltration and a ferroptosis-associated gene
signature for predicting the prognosis of patients with endometrial
cancer. Aging (Albany NY). 13:16713–16732. 2021.PubMed/NCBI
|
|
37
|
Zhang X and Yang Q: A pyroptosis-related
gene panel in prognosis prediction and immune microenvironment of
human endometrial cancer. Front Cell Dev Biol. 9:7058282021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang J, Wang Z, Zhao R, An L, Zhou X,
Zhao Y and Wang H: An integrated autophagy-related gene signature
predicts prognosis in human endometrial cancer. BMC Cancer.
20:10302020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Valero C, Lee M, Hoen D, Wang J, Nadeem Z,
Patel N, Postow MA, Shoushtari AN, Plitas G, Balachandran VP, et
al: The association between tumor mutational burden and prognosis
is dependent on treatment context. Nat Genet. 53:11–15. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao SS, Chen L, Yang J, Wu ZH, Wang XY,
Zhang Q, Liu WJ and Liu HX: Altered gut microbial profile
accompanied by abnormal fatty acid metabolism activity exacerbates
endometrial cancer progression. Microbiol Spectr. 10:e02612222022.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zu Y, Chen XF, Li Q, Zhang ST and Si LN:
PGC-1α activates SIRT3 to modulate cell proliferation and
glycolytic metabolism in breast cancer. Neoplasma. 68:352–361.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Perduca M, Nicolis S, Mannucci B, Galliano
M and Monaco HL: Human plasma retinol-binding protein (RBP4) is
also a fatty acid-binding protein. Biochim Biophys Acta Mol Cell
Biol Lipids. 1863:458–466. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee JC, Kim SH, Oh YS, Kim JH, Lee SR and
Chae HD: Increased expression of retinol-binding protein 4 in
ovarian endometrioma and its possible role in the pathogenesis of
endometriosis. Int J Mol Sci. 22:58272021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen B, Wang D, Li J, Hou Y and Qiao C:
Screening and identification of prognostic tumor-infiltrating
immune cells and genes of endometrioid endometrial adenocarcinoma:
Based on the cancer genome atlas database and bioinformatics. Front
Oncol. 10:5542142020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schug TT, Berry DC, Shaw NS, Travis SN and
Noy N: Opposing effects of retinoic acid on cell growth result from
alternate activation of two different nuclear receptors. Cell.
129:723–733. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ochiai A, Kuroda K, Ozaki R, Ikemoto Y,
Murakami K, Muter J, Matsumoto A, Itakura A, Brosens JJ and Takeda
S: Resveratrol inhibits decidualization by accelerating
downregulation of the CRABP2-RAR pathway in differentiating human
endometrial stromal cells. Cell Death Dis. 10:2762019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pavone ME, Malpani S, Dyson M and Bulun
SE: Altered retinoid signaling compromises decidualization in human
endometriotic stromal cells. Reproduction. 154:207–216. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zinovkin D and Pranjol MZ:
Tumor-infiltrated lymphocytes, macrophages, and dendritic cells in
endometrioid adenocarcinoma of corpus uteri as potential prognostic
factors: An immunohistochemical study. Int J Gynecol Cancer.
26:1207–1212. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang J, An L, Zhou X, Shi R and Wang H:
Analysis of tumor mutation burden combined with immune infiltrates
in endometrial cancer. Ann Transl Med. 9:5512021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li VD, Li KH and Li JT: TP53 mutations as
potential prognostic markers for specific cancers: analysis of data
from the cancer genome atlas and the international agency for
research on cancer TP53 database. J Cancer Res Clin Oncol.
145:625–636. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Green AK, Feinberg J and Makker V: A
review of immune checkpoint blockade therapy in endometrial cancer.
Am Soc Clin Oncol Educ Book. 40:1–7. 2020.PubMed/NCBI
|
|
52
|
Oyewole-Said D, Konduri V, Vazquez-Perez
J, Weldon SA, Levitt JM and Decker WK: Beyond T-cells: Functional
characterization of CTLA-4 expression in immune and non-immune cell
types. Front Immunol. 11:6080242020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chaudhri A, Xiao Y, Klee AN, Wang X, Zhu B
and Freeman GJ: PD-L1 binds to B7-1 only in cis on the same cell
surface. Cancer Immunol Res. 6:921–929. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kogata Y, Tanaka T, Ono YJ, Hayashi M,
Terai Y and Ohmichi M: Foretinib (GSK1363089) induces p53-dependent
apoptosis in endometrial cancer. Oncotarget. 9:22769–22784. 2018.
View Article : Google Scholar : PubMed/NCBI
|
